HCAT Stock Forecast & Price Target

Health Catalyst is positioned for a more durable, profitable growth path as it works through an early-stage transformation that simplifies operations, refocuses go-to-market execution, and highlights its differentiated data moat of 18 years of proprietary healthcare improvement data. The company’s Q1 performance showed healthy demand, with management guiding FY26 gross bookings of $22M–$26M and describing Q1 bookings as strong, while adjusted EBITDA rose to $9.1M, up 45.5% year over year, with margin expanding to 12.9%. Additional support comes from higher-margin tech and services mix improvements, expanding gross margin to 51.5%, and Project Nexus targeting about $30M of annualized run-rate savings, which should help offset transition costs and strengthen profitability.

Health Catalyst is facing a difficult fundamental reset as Vitalware’s divestiture removed a meaningful earnings contributor, with about $37 million of 2025 revenue and $11.4 million of 1H'26 adj.-EBITDA gone, while FY'26 guidance now implies a 5.7% revenue decline at the midpoint and a 42.1% drop in adj.-EBITDA. The core business remains pressured by churn, down-sell, and DOS-to-Ignite migration risk, including a $52 million ARR pool at risk with management still expecting substantial pressure through 2027 and a likely 2H'26 revenue step-down. Although the balance sheet is cleaner after debt repayment and pro forma 2Q cash was about $82 million with no debt, the company still needs clear proof that its go-forward offerings can regain growth and profitability in a weak operating environment.